Immatics (IMTX)
(Delayed Data from NSDQ)
$10.01 USD
+0.23 (2.35%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $10.00 -0.01 (-0.10%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
IMTX 10.01 +0.23(2.35%)
Will IMTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IMTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMTX
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
Immatics (IMTX) Moves 23.2% Higher: Will This Strength Last?
IMTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -19.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Immatics (IMTX)
Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies
How Much Upside is Left in Immatics (IMTX)? Wall Street Analysts Think 45.78%
Other News for IMTX
Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case
Maintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising Partnerships
Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Immatics N.V. Showcases Clinical Strides and Fiscal Health